Cantargia AB Company Profile

09:30 EST 17th December 2018 | BioPortfolio

The Board of Directors

News Articles [19 Associated News Articles listed on BioPortfolio]

Cantargia Publishes Prospectus in Connection with the List Change to Nasdaq Stockholm's Main Market

STOCKHOLM, Sept. 19, 2018 /PRNewswire/ -- On 13 September 2018, Cantargia AB (publ) ("Cantargia" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the admission of...

Cantargia Publishes Half Year Report

STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- Cantargia AB's half year report for the period January until June 2018 is now available on the company's web page

Cantargia (CANT) - Tackling tumour promoting inflammation

Edison Investment Research - Pharmaceutical & healthcare - Cantargia: With its IL1-RAP inhibitor technology, Cantargia tackles tumour-promoting inflammation by targeting IL-1 signalling pathway. Moreo...

Cantargia (CANT) - Phase IIa set to start in Q418

Edison Investment Research - Pharmaceutical & healthcare - Cantargia: Cantargia continues to progress its main R&D programme, a Phase I/IIa CANFOUR trial with its lead drug candidate, which was gi...

Cantargia Has Been Approved for Listing on the Main Market of Nasdaq Stockholm

STOCKHOLM, Sept. 13, 2018 /PRNewswire/ -- Nasdaq Stockholm's Listing Committee has approved the admission of Cantargia AB's (publ) ("Cantargia" or the "Company") shares for trading on the main mar...

Cantargia Obtains Patent Approval for the Antibody CAN04 (nidanilimab) in China

STOCKHOLM, Aug 1, 2018 /PRNewswire/ -- Cantargia AB announce that the Chinese patent authority, State Intellectual Property Office ("SIPO") has issued a formal approval concerning the company's pa...

Nasdaq Nordic: Nasdaq Stockholm Welcomes Cantargia to the Main Market

Stockholm, September 25, 2018 - Nasdaq (Nasdaq: NDAQ) announces that Cantargia AB (short name: CANTA), a small cap company within the health care sector, today will start trading of its shares on t...

Cantargia Obtains Patent Approval for the Antibody CAN04 (nidanilimab) in Japan

STOCKHOLM, Sweden, Sept. 19, 2018 /PRNewswire/ -- Cantargia AB announce that the Japanese patent authority, JPO has formally approved the company's patent application of the antibody CAN04 (nidani...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Cantargia AB

The Board of Directors

More Information about "Cantargia AB" on BioPortfolio

We have published hundreds of Cantargia AB news stories on BioPortfolio along with dozens of Cantargia AB Clinical Trials and PubMed Articles about Cantargia AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cantargia AB Companies in our database. You can also find out about relevant Cantargia AB Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record